Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

iTeos Therapeutics

Explore full profile

Drug discovery company focused on tumour and cancer treatments

Charleroi, BelgiumFounded 2011Biotech & Life Sciences
Revenue $35M Latest reported FY
Total funding $100–500M Disclosed equity funding

About iTeos Therapeutics

iTeos Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops immuno-oncology therapeutics for cancer patients. The company is focused on creating a new generation of highly differentiated treatments designed to improve outcomes for individuals with cancer.

Read full description

As a clinical-stage entity, iTeos Therapeutics is primarily engaged in advancing its product candidates through the various phases of clinical trials. The company's core activities revolve around scientific research and development aimed at pioneering novel therapies for the oncology market.

The business model is centered on the research and development of new cancer treatments. This involves substantial investment in scientific discovery and clinical studies to demonstrate the safety and effectiveness of its therapeutic candidates. The company's financial performance is closely tied to the progress of its clinical pipeline and its ability to form strategic partnerships or achieve regulatory approvals.

iTeos Therapeutics operates within the competitive biopharmaceutical industry, with a specific concentration in the immuno-oncology segment. The company's future growth depends on the successful clinical development of its product candidates and their eventual commercialization.

Source: Dealroom company data

At a glance

Founded
2011
Headquarters
Charleroi, Belgium
Listing
IPO 2020
Sector
Biotech & Life Sciences
Power Law
Thoroughbred$100M+ revenue

Latest news

Press, funding announcements and product moves mentioning iTeos Therapeutics.

See all news

Investors

27 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A15 investors entered at this stage

  • SFPIM
  • FundPlus
  • Hunza Ventures
  • Wallonie Entreprendre
  • MPM BioImpact
  • Vives Partners
  • Curative Ventures
  • HBM Partners
  • 6 Dimensions Capital
  • RA Capital Management
  • Tavistock Group
  • Boxer Capital
  • Invus
  • RTW Investments
  • WE Venture

Series B and later12 investors entered at this stage

  • Boxer Capital
  • RA Capital Management
  • Invus
  • Tavistock Group
  • HBM Partners
  • Curative Ventures
  • Vives Partners
  • 6 Dimensions Capital
  • RTW Investments
  • MPM BioImpact
  • UCLouvain
  • WE Venture

Talent

Book a demo to see the people
Employees mapped 32 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 30 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
7 countries with
team presence
🇧🇪 Belgium55.6%
🇺🇸 United States28.9%
🇫🇷 France6.7%
🇬🇧 United Kingdom2.2%
🇨🇭 Switzerland2.2%
Top 5 of 7 shown
Web traffic by country
1K monthly visits
across markets
🇺🇸 United States50%
Top 1 markets shown

Patents

Estimated portfolio value
$21M

28 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about iTeos Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See iTeos Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles